Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment

Hepatitis B virus (HBV) covalently-closed-circular (ccc)DNA is the key molecule responsible for viral persistence within infected hepatocytes. The evaluation of HBV cccDNA is crucial for the management of patients with chronic HBV infection and for the personalization of treatment. However, the need for liver biopsy is the principal obstacle for the assessment of intrahepatic HBV cccDNA. In the last decade, several studies have investigated the performance of hepatitis B core-related antigen (HBcrAg) as a surrogate of HBV cccDNA amount in the liver. In this meta-analysis, we collected 14 studies (1271 patients) investigating the correlation between serum HBcrAg and intrahepatic HBV cccDNA. Serum HBcrAg showed a high correlation with intrahepatic HBV cccDNA (r = 0.641, 95% confidence interval (CI) 0.510–0.743, p < 0.001). In a head-to-head comparison, we observed that the performance of HBcrAg was significantly superior to that of hepatitis B surface antigen (r = 0.665 vs. r = 0.475, respectively, p < 0.001). Subgroup analysis showed that the correlation between HBcrAg and intrahepatic HBV cccDNA was high, both in hepatitis B e antigen-positive and -negative patients (r = 0.678, 95% CI 0.403–0.840, p < 0.001, and r = 0.578, 95% CI 0.344–0.744, p < 0.001, respectively). In conclusion, the measurement of serum HBcrAg qualifies as a reliable non-invasive surrogate for the assessment of an intrahepatic HBV cccDNA reservoir.

Download Full-text

Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus

Journal of Investigative Medicine ◽

10.1136/jim-2018-000840 ◽

2018 ◽

Vol 67 (3) ◽

pp. 681-685 ◽

Cited By ~ 1

Author(s):

Ali Sobhy ◽

Mohammed Fakhry M. ◽

Haitham A Azeem ◽

Ahmed M Ashmawy ◽

Hamed Omar Khalifa

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Hepatitis B Virus ◽

Liver Fibrosis ◽

Hepatitis B ◽

Chronic Hepatitis C ◽

Chronic Hepatitis B ◽

Non Invasive ◽

B Virus

Several studies were performed to evaluate the degree of liver fibrosis by non-invasive markers. We aimed to assess the diagnostic value of both biglycan (BGN) and osteopontin (OPN) as non-invasive markers of hepatic fibrosis in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). This study was performed on 100 patients with CHB virus, 100 patients with CHC virus and 100 normal controls. All participants were subjected to the following laboratory tests: hemoglobin, platelet, alanine aminotransferase, aspartate aminotransferase, albumin, international normalized ratio, HBs Ag, hepatitis C virus (HCV) antibody, hepatitis B virus DNA, HCV RNA, liver biopsy, BGN and OPN. We found that BGN level was significantly increased in the CHB group compared with the controls (p<0.001), but the level was not different between the CHC group and the controls (p<0.96). OPN was increased in both the CHB and CHC groups compared with the controls (p<0.001). Positive correlation was found between fibrosis stages and BGN level of the CHB group (r=0.64; p<0.001) and between fibrosis stages and OPN level of the CHB (r=0.63; p<0.001) and CHC (r=0.59; p<0.03) groups. The area under the curve (AUC), sensitivity and specificity of BGN were 1.0, 100% and 100% in predicting fibrosis in patients with CHB, and 0.50, 26% and 78% in predicting fibrosis in patients with CHC. OPN had an AUC of 0.997, sensitivity of 96% and specificity of 100% in predicting fibrosis in patients with CHB, and 0.974, 96.5% and 100% in predicting fibrosis in patients with CHC. In conclusion, BGN and OPN could be considered non-invasive markers for liver fibrosis assessment.

Download Full-text

THE PREVALENCE LIVER FUNCTION AND IMMUNOLOGIC STATUS OF CHILDREN WITH HIV AND HEPATITIS B VIRUS COINFECTION IN ENUGU, NIGERIA

African Journal of Infectious Diseases ◽

10.21010/ajid.v10i2.1 ◽

2016 ◽

Vol 10 (2) ◽

pp. 61-68

Author(s):

Uleanya Nwachinemere Davidson ◽

Nwokoye Ikenna Chidiebele ◽

Emodi Ifeoma Josephine ◽

Obidike Egbuna Olakunle ◽

Ikefuna Anthony Nnaemeka ◽

...

Keyword(s):

Hepatitis B Virus ◽

Hepatitis B ◽

Liver Function ◽

B Virus ◽

Immunologic Status

Download Full-text

Risk factors for damaged liver function after chemotherapy in hepatitis B virus carriers with non-Hodgkin lymphoma

Genetics and Molecular Research ◽

10.4238/2015.march.30.25 ◽

2015 ◽

Vol 14 (1) ◽

pp. 2647-2653

Author(s):

X. Li ◽

X.W. Fan ◽

W. Liu ◽

L. Guo ◽

Y. Li ◽

...

Keyword(s):

Risk Factors ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Liver Function ◽

Hodgkin Lymphoma ◽

Non Hodgkin Lymphoma ◽

B Virus

Download Full-text

Non-invasive diagnosis of hepatitis B virus-related cirrhosis

World Journal of Gastroenterology ◽

10.3748/wjg.v20.i2.445 ◽

2014 ◽

Vol 20 (2) ◽

pp. 445 ◽

Cited By ~ 18

Author(s):

Sangheun Lee

Keyword(s):

Hepatitis B Virus ◽

Hepatitis B ◽

Non Invasive ◽

B Virus

Download Full-text

Diagnostic Value of Portal Vein Velocity for Portal Hypertension in Patients with Hepatitis B Virus-related Cirrhosis

Current Medical Imaging Formerly Current Medical Imaging Reviews ◽

10.2174/1573405617666210225090948 ◽

2021 ◽

Vol 17 ◽

Author(s):

Changchun Liu ◽

Sizhe Chen ◽

Xinwen Yan ◽

Yi Xiang ◽

Jialiang Hui ◽

...

Keyword(s):

Portal Hypertension ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Portal Vein ◽

Characteristic Curve ◽

Variceal Hemorrhage ◽

Non Invasive ◽

Specificity And Sensitivity ◽

B Virus ◽

Rule Out

Background: Portal vein velocity (PVV) has shown reasonable correlation with the presence of portal hypertension in patients with cirrhosis. This study aims to evaluate the value of PVV for diagnosing clinically significant portal hypertension (CSPH) and predicting the risk of variceal hemorrhage (VH) in patients with hepatitis B virus (HBV)-related cirrhosis. Material and Methods: A cohort of 166 consecutive adult patients with HBV-related cirrhosis was recruited in this retrospective study from two high-volume liver centers in China between April 2015 and April 2017. The performance of PVV and other non-invasive parameters for diagnosing CSPH and predicting risk of VH were studied. Results: PVV demonstrated the best performance for diagnosing CSPH (defined as an HVPG ≥10 mmHg) in patients with HBV-related cirrhosis among the included noninvasive predictors with the area under the receiver operating characteristic curve (AUC), specificity, and sensitivity of 0.745, 50%, and 93.5%, respectively. Other noninvasive markers, including APRI, AAR, LS, FIB-4, and diameter of portal vein, did not show sufficient performance with the AUCs of 0.565, 0.560, 0.544, 0.529, and 0.474, respectively. With regard to predicting the risk of VH (defined as an HVPG ≥12 mmHg), PPV also exhibited a moderate performance with an AUC of 0.762, which was superior to that of the aforementioned markers. By using two cutoff values of PVV to rule-out (11.65 cm/s) and rule-in (20.20 cm/s) CSPH, 30 (33.7%) patients showed definite results categories, with 23 (76.7%) patients were well classified and 7 (23.3%) were misclassified. Fifty-nine (66.3%) patients were with indeterminate results. By using PVV values of 13.10 cm/s and 21.40 cm/s to rule-out and rule-in HVPG ≥ 12mmHg, 34 (38.2%) patients has definite results, among whom 26 (76.5%) were well classified and 8 (23.5%) were misclassified. And 55 (61.8%) patients required further evaluation. Conclusion: PPV is not good enough to serve as a non-invasive parameter for identifying CSPH and predicting risk of VH in patients with HBV-related cirrhosis.

Download Full-text

Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing

Journal of Molecular Cell Biology ◽

10.1093/jmcb/mjz025 ◽

2019 ◽

Vol 11 (8) ◽

pp. 665-677 ◽

Cited By ~ 4

Author(s):

Yiyu Lu ◽

Zhaoyuan Fang ◽

Meiyi Li ◽

Qian Chen ◽

Tao Zeng ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Candidate Genes ◽

Mononuclear Cells ◽

Prediction Models ◽

Non Invasive ◽

Diagnosis And Prognosis ◽

B Virus ◽

Edge Based

Abstract Hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths in Asia and Africa. Developing effective and non-invasive biomarkers of HCC for individual patients remains an urgent task for early diagnosis and convenient monitoring. Analyzing the transcriptomic profiles of peripheral blood mononuclear cells from both healthy donors and patients with chronic HBV infection in different states (i.e. HBV carrier, chronic hepatitis B, cirrhosis, and HCC), we identified a set of 19 candidate genes according to our algorithm of dynamic network biomarkers. These genes can both characterize different stages during HCC progression and identify cirrhosis as the critical transition stage before carcinogenesis. The interaction effects (i.e. co-expressions) of candidate genes were used to build an accurate prediction model: the so-called edge-based biomarker. Considering the convenience and robustness of biomarkers in clinical applications, we performed functional analysis, validated candidate genes in other independent samples of our collected cohort, and finally selected COL5A1, HLA-DQB1, MMP2, and CDK4 to build edge panel as prediction models. We demonstrated that the edge panel had great performance in both diagnosis and prognosis in terms of precision and specificity for HCC, especially for patients with alpha-fetoprotein-negative HCC. Our study not only provides a novel edge-based biomarker for non-invasive and effective diagnosis of HBV-associated HCC to each individual patient but also introduces a new way to integrate the interaction terms of individual molecules for clinical diagnosis and prognosis from the network and dynamics perspectives.

Download Full-text